← Back to Clinical Trials
Recruiting NCT07146113
Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation
Trial Parameters
Condition Prostate Cancer
Sponsor AstraZeneca
Study Type OBSERVATIONAL
Phase N/A
Enrollment 400
Sex MALE
Min Age 18 Years
Max Age N/A
Start Date 2025-06-30
Completion 2027-06-30
Brief Summary
A multicentre observational study on treatment approaches and biomarkers in de novo metastatic hormone sensitive prostate cancer in Russian Federation
Eligibility Criteria
Inclusion Criteria: 1. Male patients aged ≥ 18 years old; 2. Signed ICF, including consent for FFPE tumor tissue sample testing; 3. De novo histologically confirmed high-aggressive (Gleason 8-10) mPC; 4. Diagnosis of mPC (metastatic prostate cancer) within 2 years prior to inclusion; 5. Availability of source medical documentation; 6. Presence of biopsy FFPE tumor tissue sample, obtained as part of standard clinical practice, which will be used for biomarker testing; 7. Unknown HRRm status. Exclusion Criteria: 1\. Participation in any interventional trial since the mPC diagnosis.